Ignite Creation Date:
2025-12-25 @ 1:19 AM
Ignite Modification Date:
2026-01-25 @ 10:45 AM
Study NCT ID:
NCT01000493
Status:
COMPLETED
Last Update Posted:
2017-09-01
First Post:
2009-10-15
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder
Sponsor:
GlaxoSmithKline
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Post-Traumatic Stress Disorder | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | efficacy | View |
| None | double-blind | View |
| None | Clinician Administered PTSD Scale | View |
| None | placebo | View |
| None | Sleep | View |
| None | safety | View |
| None | CAPS | View |
| None | neurokinin-1 antagonist | View |
| None | orvepitant | View |
| None | PTSD | View |
| None | randomized | View |
| None | Post traumatic stress disorder | View |
| None | Phase II | View |